Scott Webster

Professor of Medicines Discovery, University of Edinburgh.

[Scott Webster @prof_webster]

Jonathan is an excellent addition to the @KynosTxLtd team. I look forward to working together to build further success.

[Scott Webster @prof_webster]

Proud to have been part of the team responsible for developing this medicine. Really encouraging results for those affected by Alzheimer's disease.

[Actinogen Medical @ActinogenMed]

Watch webcast for a more in-depth look at this exciting news for @ActinogenMed announcing positive Ph 2a clinical data from its #AlzheimersDisease #biomarker study, which validates the Company’s Xanamem program.

#clinicaltrials #investors $ACW #ASX

https://t.co/KQRropgfR6

[Brian Walker @BWalker1963]

... and on the same day here are the encouraging clinical trial results from the drug that we developed to reduce cortisol action in the brain of patients with dementia @prof_webster https://t.co/ur9QKXQ7DC

[Damian Mole @DamianJMole]

Kynos is rapidly building momentum towards the clinic. Alison’s experience across large pharma and #biotech covers #finance at the #operational level as well as a #strategic outlook. A breadth of skill and experience to support Kynos achieve a strong position in the near future.

[Scott Webster @prof_webster]

@KynosTxLtd are delighted to welcome Alison Strutt who joins our senior management team as CFO.
She brings extensive strategic, transactional, and operational experience in biotech and large pharma to the company.
#appointment #biotech #leadership #CFO

[Scott Webster @prof_webster]

😥

[Scott Webster @prof_webster]

https://t.co/oAamz6Pxg6

[Scott Webster @prof_webster]

https://t.co/c4z7PsO9uN

[Enamine Ltd 🇺🇦 @EnamineLtd]

Enamine is resuming work.
Please review the new statement from our Founder and CEO, Andrey Tolmachev.
https://t.co/o6kjNeW5lz

[Scottish Enterprise News @ScotEntNews]

"Supporting companies such as Kynos Therapeutics to progress its ground-breaking medical research is a priority for @scotent" - our Director of Growth Investments, Kerry Sharp on the @EdinburghUni spin-out's financing announcement today: https://t.co/GNIFizi5lI

[Scott Webster @prof_webster]

Really happy to have support from @scotent to build our company

[Scottish Enterprise @scotent]

.@KynosTxLtd has secured £9 million to commercialise its ground-breaking drug discovery research 🤩

We’re delighted to have contributed to the funding which will help Kynos expand its team and develop a portfolio of medicines.

#Investment #WorldHealthDay
https://t.co/tOK5aPkcez

[IP Group - visionary ventures @IPGroupplc]

New portfolio company @KynosTxLtd with @epidarex @scotent @DamianJMole @prof_webster. Excited to support & you can read more here: https://t.co/E0FxIwJ0vf. #backinginnovation
👇
https://t.co/Q1p1QBFtY7

[IP Group - visionary ventures @IPGroupplc]

Great news on #WorldHealthDay with investment in new co @KynosTxLtd. Excited to support & you can read more here: https://t.co/E0FxIwJ0vf. #backinginnovation @epidarex @scotent
👇
University of Edinburgh life sciences spin-out secures major £9m injection https://t.co/zAssUvBOzn

[Scottish Business Insider @Insidermag]

Kynos Therapeutics, a life sciences spin-out from @EdinburghUni, has emerged from 'stealth mode' with £9m to finance its next phase of growth https://t.co/i66m3rCJB8

[Scott Webster @prof_webster]

Delighted to announce this investment into @KynosTxLtd

[Scott Webster @prof_webster]

@NixonLab Congratulations Mark. Very happy for you.

[Scott Webster @prof_webster]

These updates are great if you like to keep abreast of the latest advances in med chem

[Dennis X. Hu @DennisWhom]

Molecules of the Month, Jul 2021 | https://t.co/OHUX5oif6y

An ER degrader in Ph. III, 4(!) neurology candidates from Takeda, two sulfoximines, and molecule gets ubiquitylated to degrade its target

Gradually moving content to team page @drughuntersite

#chemtwitter #biotwitter

[Scott Webster @prof_webster]

@AdamRutherford You live a charmed life